← Leaderboards
Yuet W Kan
University Of California San Francisco
$9,706,494
Attributed
$9,706,494
Total exposure
12
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2005–15$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$21,312,743 · 14
By mechanism
P01$13,901,102 · 4
R01$2,903,632 · 2
T32$1,387,905 · 1
R37$1,230,732 · 1
U54$1,039,174 · 1
U01$745,950 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Francisco
Same institution · by research overlap
- Elliott P Vichinsky$12,339,152
- James H. McKerrow$11,473,832
- Maria Almira Correia$15,621,973
- Ann V Schwartz$6,324,258
- Philip Jon Rosenthal$36,168,903
Others in their field
Top investigators on “Sickle Cell Anemia”
- Russell E Ware · Duke University$48,435,687
- Michael Rutledge Debaun · Vanderbilt University Medical Center$38,268,866
- Martin H. Steinberg · Boston Medical Center$25,628,557
- Michael L. Terrin · Clinical Trials And Surveys Corporation$23,855,067
- Barbara L Kroner · Research Triangle Institute$21,141,016
- Garret A Fitzgerald · University Of Pennsylvania$20,602,198
Research focus
Sickle Cell AnemiaGene TherapyGene ExpressionThalassemiaTransfection /Expression VectorLaboratory MouseBiotechnologyGenesPrenatal DiagnosisCellsDisease /Disorder ModelGenetic Promoter ElementHematopoietic Stem CellsGenerationsIntegraseHematopoieticInduced Pluripotent Stem CellMediatingHemoglobinopathiesCell TherapyBeta ThalassemiaHereditary DiseaseComplementary DnaDouble-Stranded Rna
Grant awards (45)
Development of iPS Cells for Treatment of Hemoglobinopathies$1,291,356
P01 · FY2015 · DK · contact PI
Reprogramming iPS Cells with Exogenous and Endogenous Transcription Factor Genes$381,403
P01 · FY2015 · DK · contact PI
Development of iPS Cells for Treatment of Hemoglobinopathies$1,299,683
P01 · FY2014 · DK · contact PI
Reprogramming iPS Cells with Exogenous and Endogenous Transcription Factor Genes$381,220
P01 · FY2014 · DK · contact PI
Development of iPS Cells for Treatment of Hemoglobinopathies$1,255,622
P01 · FY2013 · DK · contact PI
Reprogramming iPS Cells with Exogenous and Endogenous Transcription Factor Genes$367,591
P01 · FY2013 · DK · contact PI
Development of iPS Cells for Treatment of Hemoglobinopathies$1,306,270
P01 · FY2012 · DK · contact PI
Reprogramming iPS Cells with Exogenous and Endogenous Transcription Factor Genes$380,629
P01 · FY2012 · DK · contact PI
Development of iPS Cells for Treatment of Hemoglobinopathies$1,333,992
P01 · FY2011 · DK · contact PI
Reprogramming iPS Cells with Exogenous and Endogenous Transcription Factor Genes$376,454
P01 · FY2011 · DK · contact PI
FETAL MONKEY MODEL FOR GENE THERAPY FOR SICKLE CELL DISEASE$27,111
P51 · FY2008 · RR · contact PI
Sickle Cell Anemia Mice Carrying Chromosomes from Four Human Haplotypes$473,679
U54 · FY2007 · HL · contact PI
FETAL MONKEY MODEL FOR GENE THERAPY FOR SICKLE CELL DISEASE$24,607
P51 · FY2007 · RR · contact PI
AAV Mediated Angiogenic Therapy for Coronary Disease$295,880
R01 · FY2006 · HL · contact PI
SCA MICE CARRYING CHROMOSOMES FROM 4 HUMAN HAPLOTYPES$286,053
U54 · FY2006 · HL · contact PI
Basic Research in Hematology and Oncology$211,888
T32 · FY2006 · DK · contact PI
FETAL MONKEY MODEL FOR GENE THERAPY FOR SICKLE CELL DISEASE$24,804
P51 · FY2006 · RR · contact PI
Abnormal Hemoglobin Synthesis -- Mechanism and Detection$435,049
R01 · FY2005 · DK
AAV Mediated Angiogenic Therapy for Coronary Disease$303,000
R01 · FY2005 · HL
SCA MICE CARRYING CHROMOSOMES FROM 4 HUMAN HAPLOTYPES$279,442
U54 · FY2005 · HL
Basic Research in Hematology and Oncology$206,775
T32 · FY2005 · DK
FETAL MONKEY MODEL FOR GENE THERAPY FOR SICKLE CELL DISEASE$27,726
P51 · FY2005 · RR
GENE THERAPY STRATEGIES FOR SICKLE CELL DISEASE$1,096,463
P01 · FY2004 · HL
Abnormal Hemoglobin Synthesis -- Mechanism and Detection$435,049
R01 · FY2004 · DK
AAV Mediated Angiogenic Therapy for Coronary Disease$303,000
R01 · FY2004 · HL
Basic Research in Hematology and Oncology$227,262
T32 · FY2004 · DK
GENE THERAPY STRATEGIES FOR SICKLE CELL DISEASE$1,085,566
P01 · FY2003 · HL
Abnormal Hemoglobin Synthesis -- Mechanism and Detection$435,049
R01 · FY2003 · DK
AAV Mediated Angiogenic Therapy for Coronary Disease$301,834
R01 · FY2003 · HL
BASIC RESEARCH IN HEMATOLOGY AND ONCOLOGY$193,898
T32 · FY2003 · DK
GENE THERAPY STRATEGIES FOR SICKLE CELL DISEASE$998,740
P01 · FY2002 · HL
Abnormal Hemoglobin Synthesis -- Mechanism and Detection$394,771
R01 · FY2002 · DK
AAV vectors expressing angiogenic factors for CHD$248,650
U01 · FY2002 · HL
BASIC RESEARCH IN HEMATOLOGY AND ONCOLOGY$206,858
T32 · FY2002 · DK
SICKLE CELL ANEMIA MOUSE MODEL$135,852
P01 · FY2002 · HL
GENE THERAPY STRATEGIES FOR SICKLE CELL DISEASE$987,595
P01 · FY2001 · HL
ABNORMAL HEMOGLOBIN SYNTHESIS--MECHANISM AND DETECTION$624,460
R37 · FY2001 · DK
AAV vectors expressing angiogenic factors for CHD$248,650
U01 · FY2001 · HL
BASIC RESEARCH IN HEMATOLOGY AND ONCOLOGY$190,146
T32 · FY2001 · DK
SICKLE CELL ANEMIA MOUSE MODEL$135,852
P01 · FY2001 · HL
GENE THERAPY STRATEGIES FOR SICKLE CELL DISEASE$950,962
P01 · FY2000 · HL
ABNORMAL HEMOGLOBIN SYNTHESIS--MECHANISM AND DETECTION$606,272
R37 · FY2000 · DK
AAV vectors expressing angiogenic factors for CHD$248,650
U01 · FY2000 · HL
BASIC RESEARCH IN HEMATOLOGY AND ONCOLOGY$151,078
T32 · FY2000 · DK
SICKLE CELL ANEMIA MOUSE MODEL$135,852
P01 · FY2000 · HL